Advisory Services Network’s ProQR Therapeutics PRQR Stock Holding History

Advisory Services Network’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$426	–	3080
2023 Q1	$426	Hold	200	–	–	﹤0.01%	3763
2022 Q4	$740	Buy	+200	New	+$262	﹤0.01%	3656

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Advisory Services Network's PRQR Position: Q2 2023 in Review

Advisory Services Network sold out of ProQR Therapeutics (PRQR) in Q2 2023, closing a stake of 200 shares — an estimated $426 sold.

Advisory Services Network first reported a position in PRQR in Q4 2022 and held it in 2 quarters. The position peaked at $740 in Q4 2022. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2023.

Advisory Services Network reported no remaining ProQR Therapeutics position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 200 ProQR Therapeutics shares in Q2 2023, an estimated $426.
Advisory Services Network first reported a position in ProQR Therapeutics in Q4 2022 and held it in 2 quarters.
Advisory Services Network's ProQR Therapeutics position peaked at $740 in Q4 2022.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.